Aurobindo Pharma has issued a statement clarifying the recent increase in the trading volume of its securities. The company states that the movement appears to be purely market-driven. Aurobindo Pharma confirms that there is no undisclosed information or pending announcements that could be influencing the stock’s price or volume. The company also affirms its ongoing commitment to regulatory compliance.
Response to Trading Activity
Aurobindo Pharma addressed recent queries regarding a notable increase in its trading volume. The company’s official statement, released on October 30, 2025, aims to provide clarity to investors and the market.
Market-Driven Movement
The company believes that the recent surge in trading volume is primarily due to market dynamics. Aurobindo Pharma emphasizes that the movement in its securities appears to be purely market driven.
No Undisclosed Information
Aurobindo Pharma explicitly confirms the absence of any undisclosed information or pending announcements that could potentially affect the company’s stock. The company asserts that, as of October 30, 2025, there are no internal developments influencing the price/volume movement of its securities.
Commitment to Compliance
Aurobindo Pharma reiterates its dedication to upholding continuous compliance with disclosure obligations. The company states it is committed to adhering to all applicable regulations.
Source: BSE
